Denali Therapeutics Inc (NASDAQ:DNLI) saw a large increase in short interest in December. As of December 29th, there was short interest totalling 2,291,611 shares, an increase of 1,101.8% from the December 15th total of 190,677 shares. Based on an average daily volume of 434,780 shares, the short-interest ratio is presently 5.3 days. Currently, 4.5% of the company’s stock are sold short.
In other news, major shareholder Douglas K. Bratton bought 275,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $4,950,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 target price on the stock. Goldman Sachs Group assumed coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued a “neutral” rating on the stock. Evercore ISI assumed coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 target price on the stock.
Shares of Denali Therapeutics (NASDAQ DNLI) opened at $17.10 on Wednesday. The company has a market capitalization of $1,500.00 and a price-to-earnings ratio of -16.60. Denali Therapeutics has a 12-month low of $14.72 and a 12-month high of $22.95.
ILLEGAL ACTIVITY WARNING: “Denali Therapeutics Inc (DNLI) Short Interest Update” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/17/denali-therapeutics-inc-dnli-short-interest-update.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.